Publications To Date

    nCOUNTER PUBLICATIONS

    Filter Publications

    PAGE 1 OF 9 | DISPLAYING 1 - 15 OF 124 RESULTS

    Liu Z. et. al., 2018 Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients., 10.1158/1078-0432.CCR-17-1350, Clin. Can. Res,, Apr 30, 2018

    Li Y. et. al., 2018 Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054, 10.1186/s40425-018-0329-7, J. Immunother, Cancer, Apr 30, 2018

    Vari F. et. al., 2018 Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL, 10.1182/blood-2017-07-796342, Blood, Apr 19, 2018

    Kim H. et. al., 2018 Development of a Validated Interferon Score Using NanoString Technology., 10.1089/jir.2017.0127., J. Interferon Cytokine Res., Apr 01, 2018

    Mu L. et. al., 2018 The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas, 10.3389/fnmol.2018.00082, Front. Mol. Neurosci., Mar 28, 2018

    Bagaria S.P. et. al., 2018 Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma, 10.3389/fonc.2018.00071, Front. Oncol., Mar 22, 2018

    Cooks T. et. al., Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246, 10.1038/s41467-018-03224-w, Nat. Commun., Feb 22, 2018

    Vari F. et. al., Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL., 10.1182/blood-2017-07-796342, Blood, Feb 15, 2018

    Sampath S. et. al., Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients, 10.18632/oncotarget.24397 , Oncotarget, Feb 02, 2018

    Revino L. et. al., Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation., 10.1172/JCI92812., JCI, Feb 01, 2018

    Ricca J.M. et. al., Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy., 10.1016/j.ymthe.2018.01.019, Mol. Therapy, Jan 25, 2018

    Janse Van Rensburg H.J. et. al., The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1., 10.1158/0008-5472.CAN-17-3139, Can. Res., Jan 16, 2018

    Luo N. et al., DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer, 10.1038/s41467-017-02630-w, Nat. Commun., Jan 16, 2018

    Zhao X. et. al., B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors, 10.1016/j.ymthe.2018.01.007, Mol. Therapy, Jan 16, 2018

    Penarando J. et. al., A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer, 10.1186/s12915-017-0472-5, BMC. Biol., Jan 10, 2018